GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » Net Change in Cash

CDIO (Cardio Diagnostics Holdings) Net Change in Cash : $6.54 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cardio Diagnostics Holdings Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Cardio Diagnostics Holdings's Net Change in Cash for the three months ended in Dec. 2024 was $5.85 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was $6.54 Mil.

Cardio Diagnostics Holdings Net Change in Cash Historical Data

The historical data trend for Cardio Diagnostics Holdings's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardio Diagnostics Holdings Net Change in Cash Chart

Cardio Diagnostics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
0.24 0.28 3.61 -2.83 6.54

Cardio Diagnostics Holdings Quarterly Data
Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.35 0.28 -0.25 0.67 5.85

Cardio Diagnostics Holdings Net Change in Cash Calculation

Cardio Diagnostics Holdings's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-4.993+-0.404+11.941+0
=6.54

Cardio Diagnostics Holdings's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.392+-0.055+7.292+0
=5.85

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardio Diagnostics Holdings Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Cardio Diagnostics Holdings's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardio Diagnostics Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » Net Change in Cash
Comparable Companies
CRIS CVM NEUP LSTA MURA ABVC UBX NNVC ALLK QTTB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Website
https://www.cardiodiagnosticsinc.com
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.
Executives
Robert Philibert director, 10 percent owner, officer: Chief Medical Officer 400 N. ABERDEEN, SUITE 900, CHICAGO IL 60642
Timur Dogan officer: Chief Technology Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Meeshanthini Dogan director, 10 percent owner, officer: Chief Executive Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Warren Hosseinion director C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Elisa V Luqman officer: Chief Financial Officer 37 HARRISON DRIVE, NORTHPORT NY 11768
Khullani Abdullahi officer: VP of Revenue and Strategy 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Brandon Sim director C/O APOLLO MEDICAL HOLDINGS, INC., 1668 S. GARFIELD AVENUE, 3RD FLOOR, ALHAMBRA CA 91801
James Intrater director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Oded Levy director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Stanley K. Lau director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Bd Holding, Inc. 10 percent owner 15 PROSPECT PLACE, IOWA CITY IA 52246
Jonathan Intrater officer: CEO 223 PALMER STREET, PALMER MA 01069
Allan Liu director 1600 PARKWOOD CIRCLE, STE 200, ATLANTA GA 30339-2119
Loren Mortman director 207 EAST 74TH STREET, APARTMENT 10F, NEW YORK NY 10021
Mana Capital Llc 10 percent owner 8 THE GREEN, SUITE A, DOVER DE 19901

Cardio Diagnostics Holdings Headlines

From GuruFocus

Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality

By Business Wire • 06-10-2024

Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters

By Business Wire • 02-12-2024

Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India

By Business Wire • 01-08-2024

Family Medicine Specialists Selects Cardio Diagnostics' Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients

By Business Wire • 11-07-2023

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

By Business Wire • 04-09-2024

Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

By Business Wire • 10-01-2024

Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions

By Business Wire • 07-29-2024

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk�

By Business Wire • 01-04-2024

Cardio Diagnostics to Participate in the Centers for Medicare and Medicaid Services' (CMS) Clinical Laboratory Fee Schedule (CLFS) Annual Meeting to Secure Medicare Payment for Its Innovative Tests

By Business Wire • 05-21-2024

Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre

By Business Wire • 04-04-2024